

INTRODUCING

Pr **myinfla™** ER

colchicine 0.5 mg
extended-release tablets

In adult patients with existing
coronary artery disease

Add Pr MYINFLA™ to standard therapies for reduction of atherothrombotic events

MYINFLA™ (colchicine extended-release tablets)
is indicated for reduction of atherothrombotic events
in adult patients with existing coronary artery disease,
in addition to standard therapies, including
LDL-C-lowering and antithrombotic drug treatment.

Recommended dosing†

0.5 mg once daily



**One pill,
once daily**



**Administered
orally**



With or without food

Avoid taking grapefruit or
grapefruit juice with MYINFLA™

*Comparative clinical significance has not been established.

†Consult the Product Monograph for complete dosage and administration information.

NEW

In adult patients with existing coronary artery disease

Add ^{Pr}MYINFLA™ to standard therapies for reduction of atherothrombotic events

A convenient, once-daily, 0.5 mg low-dose add-on to standard therapies, including LDL-C-lowering and antithrombotic drug treatment

Use your phone's camera to scan the QR code to learn more about MYINFLA™.



For more information

Please consult the Product Monograph at <https://health-products.canada.ca/dpd-bdpp/index-eng.jsp> for important information relating to contraindications, conditions of clinical use, adverse reactions, warnings and precautions, drug interactions, and dosing instructions that has not been discussed in this piece. The Product Monograph is also available by contacting our medical information department at 1-888-550-6060 or medinfo@pendopharm.com.

Reference: Myinfla™ Product Monograph. Pendopharm, Division of Pharmascience Inc. August 20, 2021.
MYINFLA™ and MYINFLA (& Design)™ are trademarks of Pharmascience Inc.
A2100052E

Made in
Canada



myinfla™ ER
colchicine 0.5 mg
extended-release tablets

